


**In the Claims**

Please cancel claims 5, 21-25 and 30-33 without prejudice to the filing of future continuing applications.

Please substitute the following claims 1-4, 10-13, 20 and 26-29 for the claims 1-4, 10-13, 20 and 26-29 now pending in the above-identified application.

1. (Currently Amended) A compound represented by the formula:



wherein A ring denotes a non-aromatic 5- ~~to~~ 7-membered nitrogen-containing heterocyclic ring ~~which may be further substituted, which contains at least one nitrogen atom in addition to carbon atoms and may have a further substituent selected from the group consisting of:~~

an optionally substituted hydrocarbon group,

an optionally halogenated lower alkoxy group,

an optionally halogenated lower alkylthio group,

a halogen atom,

an aryloxy group,

a lower alkanoyl group,

an arylcarbonyl group,

a lower alkanoyloxy group,

an arylcarbonyloxy group,

a carboxyl group,

a lower alkoxycarbonyl group,

a carbamoyl group,

a thiocarbamoyl group,

a mono-lower alkylcarbamoyl group,

a di-lower alkylcarbamoyl group,

a C<sub>6-10</sub> aryl-carbamoyl group,

an amidino group,

an imino group,  
an amino group,  
a mono-lower alkylamino group,  
a di-lower alkylamino group,  
a 3- to 6-membered cyclic amino group optionally containing 1 to 3  
heteroatoms selected from the group consisting of oxygen  
atom, sulfur atom and nitrogen atom, in addition to carbon  
atoms and one nitrogen atom,  
an alkylenedioxy group,  
a hydroxy group,  
a nitro group,  
a cyano group,  
a mercapto group,  
a sulfo group,  
a sulfinio group,  
a phosphono group,  
a sulfamoyl group,  
a mono-lower alkylsulfamoyl group,  
a di-lower alkylsulfamoyl group,  
an arylthio group,  
a lower alkylsulfinyl group,  
an arylsulfinyl group,  
a lower alkylsulfonyl group, and  
an aryl sulfonyl group;

B ring denotes a benzene ring which may be further substituted; ;

C ring denotes a dihydrofuran ring which may be further substituted; ; and

R denotes hydrogen atom or an acyl group, ;

~~provided that: (1) when A ring is a non-aromatic 5-membered nitrogen-containing heterocyclic ring substituted with a group represented by the formula  $(CH_2)_m-N(R'')-C(=O)-R'$  (wherein R' denotes an optionally substituted hydrocarbon group, an optionally substituted amino group or an optionally substituted heterocyclic group, R'' denotes hydrogen atom or an optionally substituted hydrocarbon group, and m denotes an integer of 1 to 4), B ring denotes a benzene ring which is further substituted, (2) when A ring is a non-aromatic 6-membered nitrogen-containing heterocyclic ring substituted with oxo, B ring denotes a wholly substituted benzene ring,~~

or a salt thereof.

2. (Currently Amended) The compound according to claim 1, wherein A ring is a non-aromatic 5- ~~to 7~~ -membered nitrogen-containing heterocyclic ring which may be further substituted with an optionally substituted hydrocarbon group.


3. (Currently Amended) The compound according to claim 1, wherein A ring is a non-aromatic 5- ~~to 7~~ -membered nitrogen-containing heterocyclic ring which may be further substituted with an optionally substituted lower alkyl group.

4. (Currently Amended) The compound according to claim 1, wherein A ring is a non-aromatic 5- ~~to 7~~ -membered nitrogen-containing heterocyclic ring which may be further substituted with a lower alkyl group.

Claim 5 (Cancelled)

6. (Original) The compound according to claim 1, wherein B ring is a wholly substituted benzene ring.

7. (Original) The compound according to claim 1 which is a compound represented by the formula:




wherein R<sup>4</sup> and R<sup>5</sup> are the same or different and each denotes hydrogen atom, a halogen atom, hydroxy group, amino group, or an optionally substituted hydrocarbon group which may be via oxygen atom, nitrogen atom or sulfur atom, and other symbols are as defined in claim 1, provided that both R<sup>4</sup> and R<sup>5</sup> do not denote hydrogen atom at the same time, or a salt thereof.

8. (Original) The compound according to claim 7, wherein R<sup>4</sup> and R<sup>5</sup> are the same or different and each is a lower alkyl group or a lower alkoxy group.

9. (Original) The compound according to claim 7, wherein R<sup>4</sup> and R<sup>5</sup> are a lower alkyl group.

10. (Currently Amended) The compound according to claim 1 which is a compound represented by the formula:



wherein  $R^1$  and  $R^2$  are the same or different and each denotes hydrogen atom, an optionally esterified or amidated carboxyl group or an optionally substituted hydrocarbon group,  $R^3$  denotes hydrogen atom, an optionally substituted hydrocarbon group or an optionally substituted amino group,  $R^4$  and  $R^5$  are the same or different and each denotes hydrogen atom, a halogen atom, hydroxy group, amino group, or an optionally substituted hydrocarbon group which may be via oxygen atom, nitrogen atom or sulfur atom and other symbols are as defined in claim 17, or a salt thereof.

11. (Currently Amended) The compound according to claim 10, wherein  $R^1$  is a lower alkyl group,  $R^2$  is a ~~halogen atom, hydroxy or a~~ lower alkyl group which may be substituted with an optionally substituted cyclic amino, a halogen atom or a hydroxy, and  $R^3$  is hydrogen atom or an optionally substituted phenyl group.

12. (Currently Amended) The compound according to claim 10, wherein  $R^1$  is a lower alkyl group,  $R^2$  is a ~~halogen atom, hydroxy or a~~ lower alkyl group which may be substituted with an optionally substituted cyclic amino group, a halogen atom or a hydroxy,  $R^3$  is hydrogen atom or an optionally substituted phenyl group,  $R^4$  and  $R^5$  are a lower alkyl group, and A ring is a non-aromatic 5- ~~to 7~~ -membered nitrogen-containing heterocyclic ring which may be further substituted with a lower alkyl group.

13. (Currently Amended) The compound according to claim 10, wherein  $R^1$  is a lower alkyl group,  $R^2$  is a ~~halogen atom, hydroxy or a~~ lower alkyl group which may be substituted

with an optionally substituted cyclic amino group, a halogen atom or a hydroxy, R<sup>3</sup> is hydrogen atom or an optionally substituted phenyl group, R<sup>4</sup> and R<sup>5</sup> are independently a lower alkyl group, and A ring is a non-aromatic 5-membered nitrogen-containing heterocyclic ring which may be further substituted with a lower alkyl group.

14. (Original) The compound according to claim 1 which is 1,6,7,8-tetrahydro-2,2,4,5-tetramethyl-1-(4-methylphenyl)-2H-furo[3,2-e]indole or a salt thereof.


15. (Original) The compound according to claim 1 which is 1,6,7,8-tetrahydro-2,4,5-trimethyl-2-[(4-phenylpiperidino)methyl]-2H-furo[3,2-e]indole or a salt thereof.

16. (Original) The compound according to claim 1 which is 1,6,7,8-tetrahydro-2,4,5,7,7-pentamethyl-2-[(4-phenylpiperidino)methyl]-2H-furo[3,2-e]indole or a salt thereof.

17. (Original) The compound according to claim 1 which is N-(diphenylmethyl)-1-[(1,6,7,8-tetrahydro-2,4,5,7,7-pentamethyl-2H-furo[3,2-e]indol-2-yl)methyl]-4-piperidineamine or a salt thereof.


18. (Original) A prodrug of the compound according to claim 1.

19. (Original) A process for preparing the compound according to claim 1 which comprises ring-closing a substituent X and hydroxy group on B ring of a compound represented by the formula:



wherein X denotes an optionally substituted allyl group, and other symbols are as defined in claim 1, or a salt thereof.

20. (Currently Amended) A pharmaceutical composition which comprises a compound of claim 1 ~~represented by the formula:~~




~~wherein A ring denotes a non-aromatic 5- to 7-membered nitrogen-containing heterocyclic ring which may be further substituted, B ring denotes a benzene ring which may be further substituted, C ring denotes a dihydrofuran ring which may be further substituted, R denotes hydrogen atom or an acyl group, provided that: (1) when A ring is a non-aromatic 5-membered nitrogen-containing heterocyclic ring substituted with a group represented by the formula~~

~~-(CH<sub>2</sub>)<sub>m</sub>-N(R'')-C(=O)-R' (wherein R' denotes an optionally substituted hydrocarbon group, an optionally substituted amino group or an optionally substituted heterocyclic group, R'' denotes hydrogen atom or an optionally substituted hydrocarbon group, and m denotes an integer of 1 to 4), B ring denotes a benzene ring which is further substituted; (2) when A ring is a non-aromatic 6-membered nitrogen-containing heterocyclic ring substituted with oxo, B ring denotes a wholly substituted benzene ring,~~ or a salt thereof, or a prodrug thereof and a pharmacologically acceptable carrier.



Claims 21-25 (Cancelled)


26. (Currently Amended) A method for ~~preventing or~~ treating cerebrovascular impairment, cranial trauma or neurodegenerative disease which comprises administering a compound of claim 1 ~~represented by the formula:~~



~~wherein A ring denotes a non-aromatic 5- to 7-membered nitrogen-containing heterocyclic ring which may be further substituted, B ring denotes a benzene ring which may be further substituted, C ring denotes a dihydrofuran ring which may be further substituted, R denotes hydrogen atom or an acyl group, provided that: (1) when A ring is a non-aromatic 5-membered nitrogen-containing heterocyclic ring substituted with a group represented by the formula~~


~~-(CH<sub>2</sub>)<sub>m</sub>-N(R'')-C(=O)-R' (wherein R' denotes an optionally substituted hydrocarbon group, an optionally substituted amino group or an optionally substituted heterocyclic group, R'' denotes hydrogen atom or an optionally substituted hydrocarbon group, and m denotes an integer of 1 to 4), B ring denotes a benzene ring which is further substituted, (2) when A ring is a non-aromatic 6-membered nitrogen-containing heterocyclic ring substituted with oxo, B ring denotes a wholly substituted benzene ring, or a salt thereof, or a prodrug thereof to a mammal.~~

27. (Currently Amended) A method for ~~preventing or~~ treating dysuria or urinary incontinence ~~of urine~~ which comprises administering a compound represented by the formula:




wherein Aa ring denotes a non-aromatic 5- ~~to~~ 7 -membered nitrogen-containing heterocyclic ring which may be further substituted, Ba ring denotes a benzene ring which may be further substituted, Ca ring denotes a dihydrofuran ring which may be further-substituted, and Ra denotes hydrogen atom or an acyl group, or a salt thereof, or a prodrug thereof to a mammal.

28. (Currently Amended) A method for preventing or treating restenosis after percutaneous transluminal coronary angioplasty which comprises administering a compound represented by the formula:



wherein Aa ring denotes a non-aromatic 5- ~~to~~ 7 -membered nitrogen-containing heretocyclic ring which may be further substituted, Ba ring denotes a benzene ring which may be further substituted, Ca ring denotes a dihydrofuran ring which may be further substituted, and Ra denotes hydrogen atom or an acyl group, or a salt thereof, or a prodrug thereof to a mammal.

29. (Currently Amended) A method for inhibiting lipid peroxidation which comprises administering a compound represented by the formula:



wherein Aa ring denotes a non-aromatic 5- ~~to~~ 7 -membered nitrogen-containing heretocyclic ring which may be further substituted, Ba ring denotes a benzene ring which may be further

substituted, Ca ring denotes a dihydrofuran ring which may be further substituted, and Ra denotes hydrogen atom or an acyl group, or a salt thereof, or a prodrug thereof to a mammal.

Claims 30-33 (Cancelled)